For many patients undergoing treatment for cancer, there is not just the immediate worry about beating the disease but also the longer-term prospect of surviving the harsh side effects of the drugs that saved them. Almost five years ago, On the Pulse featured a clinical trial led by Dr. Todd Cooper to study the safety and efficacy of a cancer drug called CPX-351. Cooper and his team wanted to find out if CPX-351 could help young cancer patients survive their disease without the long-term cardiac damage so often caused by other drugs.

Today, the trial has completed and results published in the Journal of Clinical Oncology show that CPX-351 is in fact effective in treating children with relapsed acute myelogenous leukemia (AML) while also showing promise in minimizing long-term heart damage.

Read the full article in the Journal of Clinical Oncology here.